Filing Flows

Filing Flows › Health Care › Enanta Pharmaceuticals (ENTA)

Enanta Pharmaceuticals (ENTA) earnings and revenue breakdown

Latest: Q3 FY26 · 10-Q filed Aug 12, 2026 · Enanta Pharmaceuticals (ENTA) Q3 FY26 earnings results →

Q3 FY26 Revenue down 22% year over year to $14.4M · 136¢ of every $1 of revenue lost · operating margin -120.0%

Enanta Pharmaceuticals made $14.4M in Q3 FY26 (-22% Y/Y). Operating margin -120.0%, net loss $19.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.

Revenue$14.4M
Year over year-22%
Operating margin-120.0%
Net earnings−$19.5M
Operating cash flow−$10.0M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $14.4M in Q3 FY26, down 22% year over year and down 16% from the previous quarter.

Operating costs exceeded revenue by $17.2M, an operating margin of -120.0%. Total costs fell 15% while revenue fell 22%. The quarter ended with a net loss of $19.5M, wider than the previous quarter's $13.1M loss.

Operating cash flow was −$10.0M. Non-cash charges added back $1.2M of depreciation and amortization and $3.7M of share-based compensation. Working capital and other items added $4.7M. Capital expenditures of $7K exceeded it, leaving free cash flow of −$10.0M.

Quarterly history

Enanta Pharmaceuticals revenue by quarterEnanta Pharmaceuticals revenue by quarter$14.6MQ4 FY24$14.9MQ2 FY25$18.3MQ3 FY25$15.1MQ4 FY25$18.6MQ1 FY26$17.2MQ2 FY26$14.4MQ3 FY26
Enanta Pharmaceuticals net earnings by quarterEnanta Pharmaceuticals net earnings by quarter−$28.8MQ4 FY24−$22.6MQ2 FY25−$18.3MQ3 FY25−$18.7MQ4 FY25−$11.9MQ1 FY26−$13.1MQ2 FY26−$19.5MQ3 FY26
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q3 FY2610-QAug 12, 2026$14.4M-22%-120.0%−$19.5M−$10.0M
Q2 FY2610-QMay 13, 2026$17.2M+15%-69.1%−$13.1M−$7.2M
Q1 FY2610-QFeb 11, 2026$18.6M+10%-60.5%−$11.9M−$11.7M
Q4 FY2510-KNov 19, 2025$15.1M+4%-121.6%−$18.7M−$6.5M
Q3 FY2510-QAug 13, 2025$18.3M+2%-103.2%−$18.3M$17.5M
Q2 FY2510-QMay 14, 2025$14.9M-12%-164.3%−$22.6M−$13.5M
Q4 FY2410-KNov 27, 2024$14.6M-23%-204.4%−$28.8M−$10.4M

Charts

Enanta Pharmaceuticals: revenue growth, year over year and quarter over quarterEnanta Pharmaceuticals: revenue growth, year over year and quarter over quarterY/YQ/Q-23%Q4 FY24-12%+2%Q2 FY25+2%+23%Q3 FY25+4%-17%Q4 FY25+10%+23%Q1 FY26+15%-8%Q2 FY26-22%-16%Q3 FY26
Latest (Q3 FY26): Y/Y -22%, Q/Q -16%.
Enanta Pharmaceuticals: where the cash came from (+) and went (−), TTM to Q3 FY26Enanta Pharmaceuticals: where the cash came from (+) and went (−), TTM to Q3 FY26Other financing$42.7MOperating cash flow−$35.3MOther investing−$17.4MCash drawn (+) / kept (−)$11.4MCapital spending−$1.6MShares issued$733KTaxes on employees’ shares−$412K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Enanta Pharmaceuticals: profit against cash, quarter by quarterEnanta Pharmaceuticals: profit against cash, quarter by quarterNet incomeOperating cash flow−$28.8M−$10.4MQ4 FY24−$22.3M−$16.8MQ1 FY25−$22.6M−$13.5MQ2 FY25−$18.3M$17.5MQ3 FY25−$18.7M−$6.5MQ4 FY25−$11.9M−$11.7MQ1 FY26−$13.1M−$7.2MQ2 FY26−$19.5M−$10.0MQ3 FY26
Latest (Q3 FY26): Net income −$19.5M, Operating cash flow −$10.0M.
Enanta Pharmaceuticals: diluted shares by fiscal yearEnanta Pharmaceuticals: diluted shares by fiscal year0MFY200MFY210MFY220MFY230MFY240MFY25
+7.0% since FY20: more shares outstanding (issuance, stock pay).
Enanta Pharmaceuticals in its industry: growth against margin (225 companies, SIC 2834)Enanta Pharmaceuticals in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXTNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMENTA (-22%, -100%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

Customers and suppliers named in filings

Buys from

About Enanta Pharmaceuticals

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.

In its own words, from its 8-K, filed Aug 10, 2026.

Enanta Pharmaceuticals against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -22% against the peers' median +7%. Operating margin: -120.0% against the peers' median 20.4%.

CompanyQuarterRevenueY/YOp. margin
ENTA Enanta PharmaceuticalsQ3 FY26$14.4M-22%-120.0%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Enanta Pharmaceuticals 10-Q on SEC EDGAR · CIK 1177648 · Pharmaceutical Preparations

13F: who owns ENTA and who is buying

Largest holders of ENTA (13F)Largest holders of ENTA (13F)Jupiter Topco LLC$53.3MJanus Henderson Group$47.7MBlackRock$47.3MKrensavage Asset Management, LLC$41.8MVanguard Group$36.3MDeep Track Capital, LP$21.1MADAR1 Capital Management, LLC$19.6MVanguard Capital Management LLC$17.7MSpruce Street Capital LP$15.9MAcadian Asset Management LLC$15.7M
Funds' net buying of ENTA by quarter (13F)Funds' net buying of ENTA by quarter (13F)−$11.2M2024-09$785K2024-12−$6.9M2025-03−$1.5M2025-06$6.2M2025-09$102M2025-12$3.2M2026-03$15.9M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on ENTA

History

Every quarter: Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results · Q2 FY25 results · Q4 FY24 results

Compare ENTA with

中文版：Enanta Pharmaceuticals（ENTA）财报

Español · Français